ARTICLE | Clinical News
Coltuximab ravtansine: Development discontinued
May 5, 2014 7:00 AM UTC
Sanofi disclosed in its 1Q14 earnings that it discontinued development of SAR3419 in ALL. The compound was in Phase II testing in patients with relapsed or refractory ALL. Sanofi plans to continue dev...